Literature DB >> 21269601

Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor.

Anders Fink-Jensen1, Lene S Schmidt, Ditte Dencker, Christina Schülein, Jürgen Wess, Gitta Wörtwein, David P D Woldbye.   

Abstract

A delicate balance exists between the central dopaminergic and cholinergic neurotransmitter systems with respect to motor function. An imbalance can result in motor dysfunction as observed in Parkinson's disease patients and in patients treated with antipsychotic compounds. Cholinergic receptor antagonists can alleviate extrapyramidal symptoms in Parkinson's disease and motor side effects induced by antipsychotics. The effects of anticholinergics are mediated by muscarinic receptors of which five subtypes (M(1)-M(5)) exist. Muscarinic M(4) receptors are found at high concentrations in motor parts of the striatum, suggesting a role for muscarinic M(4) receptors in the motor side effects of antipsychotics, and in the alleviation of these side effects by anticholinergics. Here we investigated the potential role of the muscarinic M(4) receptor in catalepsy induced by antipsychotics (haloperidol and risperidone) as well as the anti-cataleptic effects of the non-selective anticholinergic drug scopolamine in fully backcrossed muscarinic M(4) receptor knockout mice. The drug-induced catalepsy was strongly attenuated, but not abolished, in M(4) knockout mice as compared to wild-type controls. Scopolamine further attenuated the cataleptic response in M(4) knockout mice, suggesting that non-M(4) muscarinic receptors also participate in the anti-cataleptic effects. In conclusion, these data indicate an important role for M(4) receptors in antipsychotic-induced motor side effects and suggest that M(4) receptors could be a target for future pharmacological treatment of antipsychotic-induced as well as idiopathic parkinsonism.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21269601      PMCID: PMC3896864          DOI: 10.1016/j.ejphar.2011.01.018

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  35 in total

1.  Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice.

Authors:  J Gomeza; L Zhang; E Kostenis; C Felder; F Bymaster; J Brodkin; H Shannon; B Xia; C Deng; J Wess
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  mRNA for the m4 muscarinic receptor subtype is expressed in adult rat brain cholinergic neurons.

Authors:  K Sugaya; C Clamp; D Bryan; M McKinney
Journal:  Brain Res Mol Brain Res       Date:  1997-10-15

3.  Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype?

Authors:  R Gerlai
Journal:  Trends Neurosci       Date:  1996-05       Impact factor: 13.837

Review 4.  Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence.

Authors:  J Arnt; T Skarsfeldt
Journal:  Neuropsychopharmacology       Date:  1998-02       Impact factor: 7.853

5.  Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons.

Authors:  E Ince; B J Ciliax; A I Levey
Journal:  Synapse       Date:  1997-12       Impact factor: 2.562

6.  A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors.

Authors:  Jongrye Jeon; Ditte Dencker; Gitta Wörtwein; David P D Woldbye; Yinghong Cui; Albert A Davis; Allan I Levey; Günther Schütz; Thomas N Sager; Arne Mørk; Cuiling Li; Chu-Xia Deng; Anders Fink-Jensen; Jürgen Wess
Journal:  J Neurosci       Date:  2010-02-10       Impact factor: 6.167

Review 7.  Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development.

Authors:  Jürgen Wess; Richard M Eglen; Dinesh Gautam
Journal:  Nat Rev Drug Discov       Date:  2007-09       Impact factor: 84.694

Review 8.  Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review.

Authors:  Keming Gao; David E Kemp; Stephen J Ganocy; Prashant Gajwani; Guohua Xia; Joseph R Calabrese
Journal:  J Clin Psychopharmacol       Date:  2008-04       Impact factor: 3.153

9.  Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes.

Authors:  P DeBoer; E D Abercrombie
Journal:  J Pharmacol Exp Ther       Date:  1996-05       Impact factor: 4.030

Review 10.  Pharmacological differentiation of classical and novel antipsychotics.

Authors:  J Arnt
Journal:  Int Clin Psychopharmacol       Date:  1998-03       Impact factor: 1.659

View more
  19 in total

1.  An allosteric enhancer of M₄ muscarinic acetylcholine receptor function inhibits behavioral and neurochemical effects of cocaine.

Authors:  Ditte Dencker; Pia Weikop; Gunnar Sørensen; David P D Woldbye; Gitta Wörtwein; Jürgen Wess; Anders Fink-Jensen
Journal:  Psychopharmacology (Berl)       Date:  2012-05-31       Impact factor: 4.530

2.  Effects of dopamine D1-like and D2-like antagonists on cocaine discrimination in muscarinic receptor knockout mice.

Authors:  Morgane Thomsen; Simon Barak Caine
Journal:  Eur J Pharmacol       Date:  2016-02-11       Impact factor: 4.432

3.  Histone deacetylase inhibitors reverse age-related increases in side effects of haloperidol in mice.

Authors:  Janitza L Montalvo-Ortiz; Daniel W Fisher; Guadalupe Rodríguez; Deyu Fang; John G Csernansky; Hongxin Dong
Journal:  Psychopharmacology (Berl)       Date:  2017-04-18       Impact factor: 4.530

4.  Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease.

Authors:  Ditte Dencker; Morgane Thomsen; Gitta Wörtwein; Pia Weikop; Yinghong Cui; Jongrye Jeon; Jürgen Wess; Anders Fink-Jensen
Journal:  ACS Chem Neurosci       Date:  2012       Impact factor: 4.418

5.  Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100.

Authors:  Nellie E Byun; Michael Grannan; Michael Bubser; Robert L Barry; Analisa Thompson; John Rosanelli; Raajaram Gowrishankar; Nathaniel D Kelm; Stephen Damon; Thomas M Bridges; Bruce J Melancon; James C Tarr; John T Brogan; Malcolm J Avison; Ariel Y Deutch; Jürgen Wess; Michael R Wood; Craig W Lindsley; John C Gore; P Jeffrey Conn; Carrie K Jones
Journal:  Neuropsychopharmacology       Date:  2014-01-20       Impact factor: 7.853

6.  Discovery of novel N-substituted oxindoles as selective m1 and m4 muscarinic acetylcholine receptors partial agonists.

Authors:  Takaaki Sumiyoshi; Takeshi Enomoto; Kentaro Takai; Yoko Takahashi; Yasuko Konishi; Yoshiharu Uruno; Kengo Tojo; Atsushi Suwa; Harumi Matsuda; Tomokazu Nakako; Mutsuko Sakai; Atsushi Kitamura; Yasuaki Uematsu; Akihiko Kiyoshi
Journal:  ACS Med Chem Lett       Date:  2013-01-27       Impact factor: 4.345

Review 7.  Physiological roles of CNS muscarinic receptors gained from knockout mice.

Authors:  Morgane Thomsen; Gunnar Sørensen; Ditte Dencker
Journal:  Neuropharmacology       Date:  2017-09-11       Impact factor: 5.250

8.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

9.  The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtype.

Authors:  Marla L Watt; Linda Rorick-Kehn; David B Shaw; Karen M Knitowski; Anne T Quets; Amy K Chesterfield; David L McKinzie; Christian C Felder
Journal:  Neuropsychopharmacology       Date:  2013-08-02       Impact factor: 7.853

10.  Parkinsonism Driven by Antipsychotics Originates from Dopaminergic Control of Striatal Cholinergic Interneurons.

Authors:  Geetika Kharkwal; Karen Brami-Cherrier; José E Lizardi-Ortiz; Alexandra B Nelson; Maria Ramos; Daniel Del Barrio; David Sulzer; Anatol C Kreitzer; Emiliana Borrelli
Journal:  Neuron       Date:  2016-07-06       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.